Brokerages Set Sutro Biopharma Inc (STRO) PT at $23.67

Share on StockTwits

Sutro Biopharma Inc (NASDAQ:STRO) has been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.67.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. ValuEngine cut Sutro Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Piper Jaffray Companies assumed coverage on Sutro Biopharma in a research note on Monday, October 22nd. They issued an “overweight” rating and a $23.00 price target for the company. JMP Securities assumed coverage on Sutro Biopharma in a research note on Monday, October 22nd. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Cowen assumed coverage on Sutro Biopharma in a research note on Monday, October 22nd. They issued an “outperform” rating for the company.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pentwater Capital Management LP bought a new stake in shares of Sutro Biopharma in the 3rd quarter valued at approximately $1,050,000. Jennison Associates LLC acquired a new stake in Sutro Biopharma in the 3rd quarter worth approximately $2,250,000. JPMorgan Chase & Co. acquired a new stake in Sutro Biopharma in the 3rd quarter worth approximately $1,501,000. Tekla Capital Management LLC acquired a new stake in Sutro Biopharma in the 3rd quarter worth approximately $3,750,000. Finally, Monashee Investment Management LLC acquired a new stake in Sutro Biopharma in the 3rd quarter worth approximately $1,575,000. 39.97% of the stock is owned by institutional investors and hedge funds.

NASDAQ:STRO traded down $0.10 on Thursday, hitting $10.58. 8,018 shares of the company’s stock traded hands, compared to its average volume of 25,653. Sutro Biopharma has a 1 year low of $8.50 and a 1 year high of $15.90.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Wednesday, November 14th. The company reported ($21.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($21.10). The business had revenue of $7.84 million during the quarter. As a group, equities analysts forecast that Sutro Biopharma will post -4.63 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Featured Article: Understanding Average Daily Trade Volume

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pebblebrook Hotel Trust  Increases Dividend to $0.38 Per Share
Pebblebrook Hotel Trust Increases Dividend to $0.38 Per Share
APN Industria REIT  To Go Ex-Dividend on March 28th
APN Industria REIT To Go Ex-Dividend on March 28th
Volution Group PLC  Announces Dividend of GBX 1.60
Volution Group PLC Announces Dividend of GBX 1.60
Insider Selling: Ambarella Inc  VP Sells 3,700 Shares of Stock
Insider Selling: Ambarella Inc VP Sells 3,700 Shares of Stock
iShares Morningstar Mid-Cap Value ETF  Shares Bought by MML Investors Services LLC
iShares Morningstar Mid-Cap Value ETF Shares Bought by MML Investors Services LLC
Zacks: Analysts Expect Cloudera Inc  Will Announce Earnings of -$0.23 Per Share
Zacks: Analysts Expect Cloudera Inc Will Announce Earnings of -$0.23 Per Share


© 2006-2019 Ticker Report